Our business
approach

Women in laboratory

We are leading regional (CEE and CIS) manufacturer of pharmaceuticals and a leader of the Polish pharmaceutical market and a part of a multinational group. For over 80 years, trusted by patients, healthcare professionals and business partners alike.

Key Facts

750
Products in sale
270
Products under development
3
R&D Centers in Warsaw, Sieradz, Starogard Gdański
5
Manufacturing sites in Poland

Markets

POLAND:
  • Polfa Warszawa S.A. (Warsaw)
  • Polpharma (Starogard Gdański, Warsaw Duchnice, Nowa Dęba, Sieradz)

Visit our Manufacturing plants to discover more.

Strategic objectives

Polpharma is well geared to achieve strategic objectives

Drugs from our plants Our values Two men talking Meeting of four people Laboratory staff in front of the monitors

Having balanced OTC vs Rx portfolio

Being the therapeutic partner

Creating competitive advantage

Leverage local R&D and Manufacturing

Successful transformation

Synergies B2C

Consistent above market growth is reinforced through the synergies between Rx and CHC sales across specific therapeutic areas

Net sales per Therapeutic Area Rx vs CHC (2018, %)

Net sales per Therapeutic Area Rx vs CHC (2018, %) diagram

Top shared Rx & CHC ThAs:
  • Cardiology
  • Gynecology
  • Alimentary
  • Ophthalmology

TOP Rx and CHC target client synergies:
  • Cardiology
  • Ophthalmology
  • Dermatology
  • Alimentary
photo of five people's hands

Competetive advantage

Competetive advantage based on 3 pillars
photo of five people's hands
Graphic of people in circle Go to market
Therapeutic approach to customers aligning with customer objectives - moving from selling products to selling capabilities

Emphasis on best in class capabilities– balanced strong local insights and regional scale

Innovating with Digital and Traditional communication channels to customers to increase effectiveness

Insight & continuous performance on key business drivers for each therapy/ Brand area

Expertise in diversified Go to market models
Product development icon Portfolio
Pipeline aligned behind therapeutic Focus

R&D model in strong collaboration with markets leveraging Customer + Patient insights to develop added value, improved Patient experience, combinations

Therapeutic developments utilised as a platform for geographical expansion: expand the therapy areas we know how to win

Local manufacturing enabling preferential market access Poland, Russia and Kazakhstan
graphic of connected dots Business Development
Create excellence in therapeutic platforms to underpin Strategic Partnerships

Therapeutic platform – partner of choice for new launches/ Brands with potential

Partner with companies strong in a therapy in non covered markets

Co-develop complimentary therapies

License out services that we have developed to support brands

Read also

We invite you to read the next articles on our website.
Handshake

End-to-end services

End-to-end services: evaluation, pre-formulation, development, manufacturing, registration, launch and supporting services.
read more
photo of five people's hands

How we stand out

We are open to co-invest in our client’s ideas, share potential risks and responsibilities during each stage of project life-cycle.
read more

Polpharma on its websites and mobile applications (“Website”) uses cookies and other related technologies (“cookies”). Self-management of cookies is possible by changing the settings in your web browser. If you do not agree to the collection of personal data through cookies, you can change the settings in your web browser or leave the Website.

By using the Website without changing the settings in your web browser, you accept Polpharma’s use of cookies. By accepting the settings in your web browser, you agree to profiling based on the information contained in cookies. Consent may be withdrawn at any time. Withdrawal of consent does not affect the lawfulness of the processing that was carried out on the basis of consent before its withdrawal.

More information can be found in the Cookies Policy.